Henrico researchers are testing the world's first norovirus vaccine and seeking volunteers 60+ for the clinical trial at ...

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and ...

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

Researchers have developed a simple and efficient system for understanding the functions of specific norovirus genes, providing new avenues for developing antivirals and vaccines. Norovirus is the ...

Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year. ・Moderna was in focus after updated cancer vaccine data, while Novavax drew ...

Shares of Moderna MRNA rose 13% in the past week after the company announced preliminary sales for the full-year 2025, as well as business outlook for 2026 and beyond. It also outlined some expected ...